• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

HIV-1逆转录酶中的A62V和S68G突变部分恢复了与K65R突变相关的复制缺陷。

The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation.

作者信息

Svarovskaia Evguenia S, Feng Joy Y, Margot Nicolas A, Myrick Florence, Goodman Derrick, Ly John K, White Kirsten L, Kutty Nilima, Wang Ruth, Borroto-Esoda Katyna, Miller Michael D

机构信息

Gilead Sciences, Inc, 4 University Place, 4611 University Drive, Durham, NC 27707, USA.

出版信息

J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):428-36. doi: 10.1097/QAI.0b013e31817bbe93.

DOI:10.1097/QAI.0b013e31817bbe93
PMID:18614922
Abstract

BACKGROUND

The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase can be selected by abacavir, didanosine, tenofovir, and stavudine in vivo resulting in reduced susceptibility to these drugs and decreased viral replication capacity. In clinical isolates, K65R is frequently accompanied by the A62V and S68G reverse transcriptase mutations.

METHODS

The role of A62V and S68G in combination with K65R was investigated using phenotypic, viral growth competition, pre-steady-state kinetic, and excision analyses.

RESULTS

Addition of A62V and S68G to K65R caused no significant change in human immunodeficiency virus type 1 resistance to abacavir, didanosine, tenofovir, or stavudine but partially restored the replication defect of virus containing K65R. The triple mutant K65R+A62V+S68G still showed some replication defect compared with wild-type virus. Pre-steady-state kinetic analysis demonstrated that K65R resulted in a decreased rate of incorporation (kpol) for all natural dNTPs, which were partially restored to wild-type levels by addition of A62V and S68G. When added to K65R and S68G, the A62V mutation seemed to restore adenosine triphosphate-mediated excision of tenofovir to wild-type levels.

CONCLUSIONS

A62V and S68G serve as partial compensatory mutations for the K65R mutation in reverse transcriptase by improving the viral replication capacity, which is likely due to increased incorporation efficiency of the natural substrates.

摘要

背景

1型人类免疫缺陷病毒逆转录酶中的K65R突变可在体内被阿巴卡韦、去羟肌苷、替诺福韦和司他夫定选择出来,导致对这些药物的敏感性降低以及病毒复制能力下降。在临床分离株中,K65R常常伴有A62V和S68G逆转录酶突变。

方法

使用表型、病毒生长竞争、前稳态动力学和切除分析研究A62V和S68G与K65R组合的作用。

结果

在K65R中添加A62V和S68G对1型人类免疫缺陷病毒对阿巴卡韦、去羟肌苷、替诺福韦或司他夫定的耐药性没有显著影响,但部分恢复了含有K65R病毒的复制缺陷。与野生型病毒相比,三重突变体K65R+A62V+S68G仍表现出一些复制缺陷。前稳态动力学分析表明,K65R导致所有天然脱氧核苷三磷酸的掺入率(kpol)降低,添加A62V和S68G后,其部分恢复到野生型水平。当添加到K65R和S68G中时,A62V突变似乎将三磷酸腺苷介导的替诺福韦切除恢复到野生型水平。

结论

A62V和S68G通过提高病毒复制能力作为逆转录酶中K65R突变的部分补偿性突变,这可能是由于天然底物的掺入效率增加所致。

相似文献

1
The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation.HIV-1逆转录酶中的A62V和S68G突变部分恢复了与K65R突变相关的复制缺陷。
J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):428-36. doi: 10.1097/QAI.0b013e31817bbe93.
2
K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine.携带和不携带S68的K65R:在大多数对阿巴卡韦、去羟肌苷和司他夫定治疗失败的患者体内检测到的一种新的耐药谱。
Antivir Ther. 2003 Apr;8(2):173-82.
3
The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations.人类免疫缺陷病毒1型逆转录酶中的K65R突变与胸苷类似物突变表现出双向表型拮抗作用。
J Virol. 2006 May;80(10):4971-7. doi: 10.1128/JVI.80.10.4971-4977.2006.
4
The S68G polymorphism is a compensatory mutation associated with the drug resistance mutation K65R in CRF01_AE strains.S68G 多态性是与 CRF01_AE 株中耐药突变 K65R 相关的补偿性突变。
BMC Infect Dis. 2020 Feb 11;20(1):123. doi: 10.1186/s12879-020-4836-z.
5
Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database.商业数据库中K65R、L74V及其他HIV-1逆转录酶耐药性突变的流行情况、基因型关联及表型特征
Antivir Ther. 2008;13(2):189-97.
6
Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase.与人类免疫缺陷病毒1型逆转录酶中K70G和M184V突变相关的新型耐药模式。
Antimicrob Agents Chemother. 2007 Dec;51(12):4489-91. doi: 10.1128/AAC.00687-07. Epub 2007 Sep 17.
7
Molecular basis of antagonism between K70E and K65R tenofovir-associated mutations in HIV-1 reverse transcriptase.HIV-1逆转录酶中K70E和K65R替诺福韦相关突变之间拮抗作用的分子基础。
Antiviral Res. 2007 Sep;75(3):210-8. doi: 10.1016/j.antiviral.2007.03.006. Epub 2007 Apr 4.
8
Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors.人类免疫缺陷病毒1型逆转录酶中的K70E突变赋予对核苷类逆转录酶抑制剂耐药性的分子机制。
Antimicrob Agents Chemother. 2007 Jan;51(1):48-53. doi: 10.1128/AAC.00683-06. Epub 2006 Nov 6.
9
Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity.具有逆转录酶突变K65R和K65R+M184V的1型人类免疫缺陷病毒耐药性的分子机制及其对酶功能和病毒复制能力的影响。
Antimicrob Agents Chemother. 2002 Nov;46(11):3437-46. doi: 10.1128/AAC.46.11.3437-3446.2002.
10
The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients.初治患者中HIV-1逆转录酶K65R突变的流行情况及决定因素
AIDS. 2002 Oct 18;16(15):2087-9. doi: 10.1097/00002030-200210180-00018.

引用本文的文献

1
Thymidine Analogue Mutations with M184V Significantly Decrease Phenotypic Susceptibility of HIV-1 Subtype C Reverse Transcriptase to Islatravir.携带M184V的胸苷类似物突变显著降低HIV-1 C亚型逆转录酶对依斯拉曲韦的表型敏感性。
Viruses. 2024 Dec 6;16(12):1888. doi: 10.3390/v16121888.
2
Distinct Clusters of HIV-1 CRF01_AE in Zhejiang, China: High-Risk Transmission Cluster 4 Requires Heightened Surveillance.中国浙江不同的HIV-1 CRF01_AE簇:高危传播簇4需要加强监测。
Infect Drug Resist. 2024 Oct 11;17:4333-4342. doi: 10.2147/IDR.S480192. eCollection 2024.
3
HIV-1 Resistance to Islatravir/Tenofovir Combination Therapy in Wild-Type or NRTI-Resistant Strains of Diverse HIV-1 Subtypes.
HIV-1 对伊拉曲韦/替诺福韦复方制剂治疗的耐药性:野生型或非核苷类逆转录酶抑制剂耐药株的多种 HIV-1 亚型。
Viruses. 2023 Sep 25;15(10):1990. doi: 10.3390/v15101990.
4
Antiretroviral therapy resistance mutations among HIV infected people in Kazakhstan.哈萨克斯坦 HIV 感染者中的抗逆转录病毒治疗耐药突变。
Sci Rep. 2022 Oct 13;12(1):17195. doi: 10.1038/s41598-022-22163-7.
5
Genetic Diversity and Low Therapeutic Impact of Variant-Specific Markers in HIV-1 Pol Proteins.HIV-1多聚蛋白中变异特异性标志物的遗传多样性及低治疗影响
Front Microbiol. 2022 Jul 14;13:866705. doi: 10.3389/fmicb.2022.866705. eCollection 2022.
6
The S68G polymorphism is a compensatory mutation associated with the drug resistance mutation K65R in CRF01_AE strains.S68G 多态性是与 CRF01_AE 株中耐药突变 K65R 相关的补偿性突变。
BMC Infect Dis. 2020 Feb 11;20(1):123. doi: 10.1186/s12879-020-4836-z.
7
Human Immunodeficiency Virus Type 1 Drug Resistance Mutations Update.1型人类免疫缺陷病毒耐药突变更新
J Infect Dis. 2017 Dec 1;216(suppl_9):S843-S846. doi: 10.1093/infdis/jix398.
8
Week 48 resistance analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF in HIV-1 infected women (WAVES study GS-US-236-0128).埃替拉韦仑/考比司他/恩曲他滨/替诺福韦酯与阿扎那韦+利托那韦+恩曲他滨/替诺福韦酯在HIV-1感染女性中的第48周耐药性分析(WAVES研究GS-US-236-0128)
HIV Clin Trials. 2017 Jul;18(4):164-173. doi: 10.1080/15284336.2017.1370059.
9
Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration.接受世界卫生组织推荐的含替诺福韦一线方案的个体中病毒学失败的突变相关性:一项国际合作。
EBioMedicine. 2017 Apr;18:225-235. doi: 10.1016/j.ebiom.2017.03.024. Epub 2017 Mar 19.
10
Genome-Wide Association Study of HIV Whole Genome Sequences Validated using Drug Resistance.利用耐药性验证的HIV全基因组序列全基因组关联研究
PLoS One. 2016 Sep 27;11(9):e0163746. doi: 10.1371/journal.pone.0163746. eCollection 2016.